# What a Large Sepsis Trial Found About Thymosin Alpha 1

- Article ID: research-376
- Product: Thymosin Alpha-1 (thymosin-alpha-1-569)
- Canonical page: https://heritagebiolabs.com/research-library/articles/376-what-a-large-sepsis-trial-found-about-thymosin-alpha-1
- Product collection: https://heritagebiolabs.com/research-library/products/thymosin-alpha-1
- Product page: https://heritagebiolabs.com/product/thymosin-alpha-1-569
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Some help regulate the way immune cells respond to signals. Thymosin alpha-1 is a 28-amino-acid peptide studied in immune regulation, and thymalfasin is a drug form of it. The phase 3 TESTS trial asked whether adding thymosin alpha-1 to the care of adults with sepsis reduced death within 28 days. The original 2025 report falls outside the preferred one-year window, but it directly answers this survival question. [1]

Sepsis is a serious illness in which the body's response to an infection can injure its own organs. Some people with sepsis show signs of reduced immune function. That observation provides a rationale for studying immune responses, but it does not tell us whether changing a particular signal helps a broad group of patients. Jianfeng Wu and colleagues randomized 1,106 adults at 22 centers in China to thymosin alpha-1 or placebo. A total of 1,089 participants received at least one study exposure and were included in the primary analysis. [1]

Within 28 days, 127 of 542 people in the thymosin alpha-1 group and 132 of 547 in the placebo group had died. That was 23.4 percent and 24.1 percent, respectively. The corrected analysis estimated a hazard ratio of 0.97, with a 95 percent confidence interval from 0.76 to 1.24. The ratio compares the rates of death over the follow-up between the groups. A value of 1 would indicate the same rate under the model, and the interval includes 1. The trial therefore did not establish a reduction in deaths within 28 days. The journal correction changed the estimate slightly and left that interpretation intact. [1, 3]

The trial also measured organ dysfunction, new infections and the number of days participants were free of some forms of life support. It found no statistically clear differences on these secondary measures. At enrollment, almost everyone had an abnormal result on at least one immune measurement. Those measurements help explain why the researchers studied the immune system in sepsis. They do not establish that correcting any particular measurement would improve the outcomes patients experience. [1]

The investigators reported patterns in some subgroups, including a possible difference by age. A subgroup contains fewer participants than the trial as a whole, and looking at several subgroups creates more chances to see a pattern that might not repeat. The result can guide a future study designed around a specific question. The overall comparison remains the best answer from TESTS for the full group enrolled. [1, 3]

A newer registered study asks a narrower question about a blood marker in people selected for signs of suppressed immune function. It has not reported results and is designed primarily to study the marker. That investigation does not overturn the completed survival comparison. Together the studies illustrate why testing a change in an immune marker and testing whether people live longer are distinct tasks. [1, 2]

## Sources

1. Wu J et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ (2025-01-15, corrected full text). <https://pmc.ncbi.nlm.nih.gov/articles/PMC11780596/>
2. Shanghai Zhongshan Hospital. A Prospective, Randomized, Controlled Mechanism Study of Thymosin Alpha-1 in Reshaping the Immune Resilience Trajectory of Immunosuppressed Sepsis Patients. ClinicalTrials.gov NCT07866118 (first posted 2026-10-08). <https://clinicaltrials.gov/study/NCT07866118>
3. Wu J et al. Correction to the TESTS phase 3 trial report. BMJ (2025-05-30). <https://pmc.ncbi.nlm.nih.gov/articles/PMC12123687/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 076 - Thymosin Alpha-1.docx; article 376; content SHA-256 6572a3ce1af15dc7bf6bcef0f1fc335241d39c291195a4c0fdc3c05f9281dbcc.
